top of page
Browse by category
Search
ENDRA reveals enhanced Strategy to enable the early detection and management of metabolic diseases facilitated by emerging GLP-1 therapies
ENDRA Life Sciences has revealed a new strategic direction to develop and deploy its Thermo-Acoustic Enhanced UltraSound system (TAEUS)...
SUMMIT: Tirzepatide benefits people with obesity, kidney disease and heart failure
Tirzepatide improves kidney function and cardiovascular outcomes among patients with obesity and heart failure with preserved ejection...
By-Band-Sleeve trial: RYGB betters LSG on weight loss and quality-of-life outcomes
Outcomes from the By-Band-Sleeve trial has confirmed the safety and effectiveness of bariatric and metabolic surgery (BMS) and that...
SOUL trial: Oral semaglutide 14 mg demonstrated superior reduction in risk of CV events
e full results from the SOUL cardiovascular outcomes trial, investigating the effects of Rybelsus (semaglutide) tablets 14 mg on reducing...
Analysis of SCORE and PRIDE studies shows semaglutide results in improved functional outcomes, health-related quality of life and CV events
Analysis of the SCORE and PRIDE studies shows semaglutide results in improved functional outcomes, health-related quality of life and CV...
Expanding access to anti-obesity medications delivers 13% return on investment for society
A USC Schaeffer Center white paper entitled, ‘Lifetime Social Returns From Expanding Access to Anti-Obesity Medication’, finds expanded...
Browse by tag
bottom of page